VTYX 2.24 (-1.75%)
US92332V1070BiotechnologyBiotechnology

Ventyx Biosciences (VTYX) Stock Highlights

2.24 | -1.75%
2024-12-21 06:32:23
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Statistics

Range Today
2.24 2.36
Volume Today 4.76M
Range 1 Year
1.67 11.48
Volume 1 Year 517.79M
Range 3 Year
1.67 47.25
Volume 3 Year 905.66M
Range 10 Year
1.67 47.25
Volume 10 Year 918.44M

Highlights

Market Capitalization 158.3M (small)
Floating Shares 49.71M
Current Price 2.24
Price To Earnings -0.82
Price To Book 0.56
Earnings Per Share -2.73
Payout Ratio 0%

Performance

Latest -1.75%
1 Month +23.76%
3 Months -4.27%
6 Months -18.84%
1 Year +4.19%
3 Years -84.37%
5 Years -87.99%
10 Years -87.99%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.